Topics

Trovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers

00:07 EDT 9 Jul 2019 | Drugs.com

SAN DIEGO, July 9, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company, today announced the initiation of patient enrollment of its...

Original Article: Trovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers

NEXT ARTICLE

More From BioPortfolio on "Trovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers"

Quick Search

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...